Study experimental plan
The study will be proposed by breast nurses or physician oncologists to patients who meet the eligibility criteria. An explanation of the study and an information note will be given to them. Patients will be enrolled in the study once provided their written informed consent. Then, the randomization will be performed on the eCRF portal, stratified on the type of hormone therapy (Aromatase Inhibitor (AI) or Tamoxifen), as these treatments differ in terms of patients’ age at prescription, tolerance profile and adherence difficulties.Patients will be assigned, according to a 1:1 randomization, to one of the following arms:
Experimental arm: WEBAPPAC web-application support (WEBAPPAC arm).Control arm: standard support.The patients will be recruited over 30 months. Their participation will last 18 months.